Bioavailability of orally administered rhGM-CSF: A single-dose, randomized, open-label, two-period crossover trial

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Zhang, Wenping ^a,b   Lv, Zhengbing ^b   Nie, Zuoming ^b   Chen, Guogang ^c   Chen, Jian ^b   Sheng, Qing ^b   Yu, Wei ^b   Jin, Yongfeng ^a   Wu, Xiangfu ^b,d   Zhang, Yaozhou ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c Zhejiang Chinagene Biopharmaceutical Co Ltd   (China)

^d INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLASMA PROTEIN;

ADULT; AMINO ACID SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME; TIME OF FLIGHT MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; ADOLESCENT; BIOAVAILABILITY; BLOOD; CHEMISTRY; DOSE RESPONSE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PEPTIDE MAPPING; SUBCUTANEOUS DRUG ADMINISTRATION;

BOMBYX MORI;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MASS SPECTROMETRY; PEPTIDE MAPPING; TIME FACTORS;

EID: 65649122298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005353     Document Type: Article

References (32)

1. Gasson JC (1991) Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 77: 1131-1145.
2. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, et al. (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545-1552.
3. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, et al. (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319: 593-598.
4. Hord JD, Gay JC, Whitlock JA, Janco RL, Edwards JR, et al. (1995) Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia. J Pediatr Hematol Oncol 17: 140-144.
5. Badaró R, Nascimento C, Carvalho JS, Badaro F, Russo D, et al. (1994) Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 170: 413-418.
6. Hardy D, Spector S, Polsky B, Crumpacker C, Van der Horst C, et al. (1994) Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis 13: S34-S40.
7. Chen J, Wu XF, Zhang YZ (2006) Expression, purification and characterization of human GM-CSF using silkworm pupae (Bombyx mori) as a bioreactor. J Biotechnol 123: 236-247.
8. Hussein AM, Ross M, Vredenburgh J, Meisenberg B, Hars V, et al. (1995) Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Eur J Haematol 55: 348-356.
9. Krumwieh D, Weinmann E, Seiler FR (1988) Human recombinant derived IL-3 and GM-CSF in hematopoiesis of normal cynomolgus monkeys. Behring Inst Mitt 83: 250-257.
10. Zhang YZ, Chen J, Lv ZB, Nie ZM, Zhang XY, et al. (2006) Can 29 kDa rhGM-CSF expressed by silkworm pupae bioreactor bring into effect as active cytokine through orally administration? Eur J Pharmaceut Sci 28: 212-223.
11. Chen J, Nie ZM, Lv ZB, Zhu CG, Xu CZ, et al. (2007) Large-scale purification of human granulocyte-macrophage colony-stimulating factor expressed in Bombyx mori pupae. Appl Biochem Biotechnol 141: 149-160.
12. (2003) Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products general considerations. In: US Department of Health and Human Services. US Food and Drug Administration CfDEaRC, editor. http://www.fdagov/cder/guidance/5356fnlpdf.
13. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680.
14. Chalasani KB, Russell GJ, Yandrapu SK, Diwan PV, Jain SK (2007) A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Rel 117: 421-429.
15. T Borchardt R, Jeffrey Aubé, Siahaan TJ, Gangwar S, Pauletti GM (1997) Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 27: 235-256.
16. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, et al. (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386: 410-414.
17. Lee SY, Huang CK, Zhang TF, Schofield BH, Burks AW, et al. (2001) Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. Clin Immunol 101: 220-228.
18. Marinaro M, Boyaka PN, Finkelman FD, Kiyono H, Jackson RJ, et al. (1997) Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 185: 415-427.
19. Jauhiainen T, Wuolle K, Vapaatalo H, Kerojoki O, Nurmela K, et al. (2007) Oral absorption, tissue distribution and excretion of a radiolabelled analog of a milk-derived antihypertensive peptide, Ile-Pro-Pro, in rats. Int Dairy J 17: 1216-1223.
20. Gersting JA, Kotto-Kome CA, Dua Y, Christensen RD, Calhoun DA (2003) Bioavailability of granulocyte colony-stimulating factor administered enterally to suckling mice. Pharmacological Res 48: 643-647.
21. Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, et al. (1999) Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz) 47: 377-385.
22. Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, et al. (2002) Colostrinin proline-rich polypeptide complex from ovine colostrum-a long-term study of its efficacy in Alzheimer's disease. Med Sci Monit 8: 193-196.
23. Naylor PH, Naylor CW, Hendrix S, Leveque FG (1999) Oral administration of interferon-alpha induces a transient decline in oral mucosal immunoglobulins and an increase in interleukin-5. J Interferon Cytokine Res 19: 953-959.
24. Gong ZH, Jin YF, Zhang YZ (2005) Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes. J Biotechnol 119: 93-105.
25. Miller LK (1988) Baculoviruses as gene expression vectors. Annu Rev Microbiol 42: 177-199.
26. Lu M, Farrell PJ, Johnson R, Iatrou K (1997) A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells. J Biol Chem 272: 30724-30728.
27. Shrivastava B, Ghosh AK (2003) Protein purification, cDNA cloning and characterization of a protease inhibitor from the Indian tasar silkworm, Antheraea mylitta. Insect Biochem Mol Biol 33: 1025-1033.
28. He N, Yakiyama M, Fujii H, Banno Y, Yamamoto K (2003) Genomic structure and expression analysis of the gene encoding a silkworm basic Kunitz-type chymotrypsin inhibitor. Biochim Biophys Acta 1628: 71-77.
29. Shiba H, Uchida D, Kobayashi H, Natori M (2001) Involvement of cathepsin B-and L-like proteinases in silk gland histolysis during metamorphosis of Bombyx mori. Arch Biochem Biophys 390: 28-34.
30. Shirai K, Fujii H, Doira H, Iwamoto H (2000) Synthesis and resorption of a humoral chymotrypsin inhibitor, CI-8, by fat body of the silkworm, Bombyx mori. Insect Biochem Mol Biol 30: 363-368.
31. Yamamoto Y, Watabe S, Kageyama T, Takahashi SY (1999) A novel inhibitor protein for Bombyx cysteine proteinase is homologous to propeptide regions of cysteine proteinases. FEBS Lett 448: 257-260.
32. Sasaki T (1978) Chymotrypsin inhibitors from hemolymph of the silkworm, Bombyx mori. J Biochem 84: 267-276.